GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Buildings And Improvements

GlaxoSmithKline Pakistan (KAR:GLAXO) Buildings And Improvements : ₨335 Mil (As of Mar. 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Buildings And Improvements?

GlaxoSmithKline Pakistan's quarterly buildings and improvements increased from Sep. 2024 (₨203 Mil) to Dec. 2024 (₨3,277 Mil) but then declined from Dec. 2024 (₨3,277 Mil) to Mar. 2025 (₨335 Mil).

GlaxoSmithKline Pakistan's annual buildings and improvements increased from Dec. 2022 (₨3,069 Mil) to Dec. 2023 (₨3,268 Mil) and increased from Dec. 2023 (₨3,268 Mil) to Dec. 2024 (₨3,277 Mil).


GlaxoSmithKline Pakistan Buildings And Improvements Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Buildings And Improvements Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,951.21 2,997.62 3,068.66 3,267.84 3,277.28

GlaxoSmithKline Pakistan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.41 173.89 203.48 3,277.28 335.29

GlaxoSmithKline Pakistan Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines